Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
10.06
+0.13 (1.31%)
At close: Dec 19, 2025, 4:00 PM EST
10.15
+0.09 (0.89%)
After-hours: Dec 19, 2025, 6:59 PM EST
Delcath Systems Revenue
Delcath Systems had revenue of $20.56M in the quarter ending September 30, 2025, with 83.60% growth. This brings the company's revenue in the last twelve months to $79.60M, up 251.54% year-over-year. In the year 2024, Delcath Systems had annual revenue of $37.21M with 1,701.69% growth.
Revenue (ttm)
$79.60M
Revenue Growth
+251.54%
P/S Ratio
4.39
Revenue / Employee
$829,198
Employees
96
Market Cap
355.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.21M | 35.14M | 1,701.69% |
| Dec 31, 2023 | 2.07M | -654.00K | -24.05% |
| Dec 31, 2022 | 2.72M | -836.00K | -23.52% |
| Dec 31, 2021 | 3.56M | 1.91M | 115.98% |
| Dec 31, 2020 | 1.65M | 66.00K | 4.18% |
| Dec 31, 2019 | 1.58M | -1.83M | -53.62% |
| Dec 31, 2018 | 3.41M | 692.00K | 25.49% |
| Dec 31, 2017 | 2.72M | 723.00K | 36.30% |
| Dec 31, 2016 | 1.99M | 245.00K | 14.02% |
| Dec 31, 2015 | 1.75M | 678.00K | 63.42% |
| Dec 31, 2014 | 1.07M | 279.00K | 35.32% |
| Dec 31, 2013 | 790.00K | 98.00K | 14.16% |
| Dec 31, 2012 | 692.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DCTH News
- 17 days ago - Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma - Business Wire
- 4 weeks ago - Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program - Business Wire
- 4 weeks ago - Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma - Business Wire
- 5 weeks ago - Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients - Business Wire
- 6 weeks ago - Delcath Systems to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Delcath: Temporary Headwinds Are No Cause For Concern - Seeking Alpha
- 6 weeks ago - Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript - Seeking Alpha